Risperdal Trial Concludes with $2.5 Million Damage Award to Plaintiff

Published on March 2, 2015 by Laurie Villanueva

Text-Size:A A A+

 

The first trial for a Risperdal lawsuit alleging male breast growth concluded at the end of February with a $2.5 million verdict in favor of the plaintiff, court documents indicate.

According to a ruling on February 24th, jurors overhearing arguments in the Philadelphia Court of Common Pleas determined that the man’s injuries occurred because Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, failed to adequately warn consumers about the drug’s association with gynecomastia, a complication referring to male breast development.  As a teenager taking the antipsychotic medication, the plaintiff in this case developed 46 DD breasts that necessitated a mastectomy to remove the excess tissue. This Risperdal gynecomastia case was the first to be heard in a consolidated litigation in the Philadelphia Court of Common Pleas.

According to a report from Philly.com, an attorney for the plaintiff owed his damage award to jurors hearing certain arguments about Johnson & Johnson and Janssen’s handling of Risperdal that revealed its failure to warn regulators about product issues, which likely endangered thousands. Claims in this antipsychotic drug lawsuit are similar to more than 1,270 others now filed in Philadelphia, many of which by men who allege pain, swelling, lactations and other painful and embarrassing side effects of Risperdal gynecomastia.

J&J and Janssen Vow to Appeal Risperdal Gynecomastia Verdict

“The jury in Philadelphia heard evidence that was never presented to the FDA by an American drug company,” he said, which might have been in reference to a former U.S. Food and Drug Administration (FDA) commissioner’s testimony that said the companies knew about Risperdal problems as early as 2001. “If there was ever a clear failure-to-warn case, this was it,” the lawyer added.

Where this Risperdal verdict was met with satisfaction on the plaintiff’s end, it was seen as cause for appeal by Johnson & Johnson and Janssen. A spokesperson for the company said officials were “disappointed” by the trial’s outcome and plan to try and overturn the Court’s decision, before adding that Janssen officials “firmly believe this verdict should be overturned.”

Considering a Risperdal Lawsuit?

Call a Risperdal lawyer at our Firm for a free and confidential evaluation of your potential lawsuit involving the antipsychotic medication. Contact our Firm for advice on the legal process of filing a claim seeking compensation for lost wages, medical bills and other damages at.